التفاصيل البيبلوغرافية
| العنوان: |
A safety and feasibility study of cell therapy in dilated cardiomyopathy. |
| المؤلفون: |
Martino HF; Instituto Nacional de Cardiologia, Rio de Janeiro, RJ, Brasil., Oliveira PS, Souza FC, Costa PC, Assunção E Silva E, Villela R, Gaze M, Weitzel LH, Oliveira A Jr, Muccillo FB, Arvelo SN, Sá R, Guimarães TC, Tura BR, Campos de Carvalho AC |
| المصدر: |
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas [Braz J Med Biol Res] 2010 Oct; Vol. 43 (10), pp. 989-95. Date of Electronic Publication: 2010 Sep 24. |
| نوع المنشور: |
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: Associação Brasileira de Divulgação Científica Country of Publication: Brazil NLM ID: 8112917 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1414-431X (Electronic) Linking ISSN: 0100879X NLM ISO Abbreviation: Braz J Med Biol Res Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: [SP, Brasil : Associação Brasileira de Divulgação Científica, 1981- |
| مواضيع طبية MeSH: |
Bone Marrow Transplantation*, Cardiomyopathy, Dilated/*surgery, Adult ; Aged ; Feasibility Studies ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Treatment Outcome ; Young Adult |
| مستخلص: |
The aim of this study was to determine if bone marrow mononuclear cell (BMMC) transplantation is safe for moderate to severe idiopathic dilated cardiomyopathy (IDC). Clinical trials have shown that this procedure is safe and effective for ischemic patients, but little information is available regarding non-ischemic patients. Twenty-four patients with IDC, optimized therapy, age 46 ± 11.6 years, 17 males, NYHA classes II-IV, and left ventricular ejection fraction <35% were enrolled in the study. Clinical evaluation at baseline and 6 months after stem cell therapy to assess heart function included echocardiogram, magnetic resonance imaging, cardiopulmonary test, Minnesota Quality of Life Questionnaire, and NYHA classification. After cell transplantation 1 patient showed a transient increase in enzyme levels and 2 patients presented arrhythmias that were reversed within 72 h. Four patients died during follow-up, between 6 and 12 weeks after therapy. Clinical evaluation showed improvement in most patients as reflected by statistically significant decreases in Minnesota Quality of Life Questionnaire (63 ± 17.9 baseline vs 28.8 ± 16.75 at 6 months) and in class III-IV NYHA patients (18/24 baseline vs 2/20 at 6 months). Cardiopulmonary exercise tests demonstrated increased peak oxygen consumption (12.2 ± 2.4 at baseline vs 15.8 ± 7.1 mL·kg⁻¹·min⁻¹ at 6 months) and walked distance (377.2 ± 85.4 vs 444.1 ± 77.9 m at 6 months) in the 6-min walk test, which was not accompanied by increased left ventricular ejection fraction. Our findings indicate that BMMC therapy in IDC patients with severe ventricular dysfunction is feasible and that larger, randomized and placebo-controlled trials are warranted. |
| تواريخ الأحداث: |
Date Created: 20100930 Date Completed: 20110504 Latest Revision: 20190606 |
| رمز التحديث: |
20231215 |
| DOI: |
10.1590/s0100-879x2010007500093 |
| PMID: |
20878013 |
| قاعدة البيانات: |
MEDLINE |
Full Text Finder